X0708 D LIVE 0001662774 Quince Therapeutics, Inc. 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 415-910-5717 CALIFORNIA None Cortexyme, Inc. Corporation true Dirk Thye 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Brigette Roberts 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Charles Ryan 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer Brendan Hannah 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Executive Officer David Lamond 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director Christopher Senner 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director June Bray 611 Gateway Blvd., Suite 273 South San Francisco CA CALIFORNIA 94080 Director Biotechnology Decline to Disclose 06b false 2026-05-18 true true true true true The Issuer issued 2,210,899 shares of common stock, 52,153.299 shares of preferred stock, and warrants to purchase up to 7,410.644 shares of preferred stock in connection with its acquisition of Orphai Technologies, Inc. 0 LifeSci Capital 000168404 None None 1700 Broadway, 40th Floor New York NY NEW YORK 10019 All States 7387671 0 7387671 Offering amount includes aggregate gross proceeds that may be received in the future upon the cash exercise in full of the warrants. false 66 1800000 0 0 false Quince Therapeutics, Inc. /s/ Dirk Thye Dirk Thye Chief Executive Officer 2026-06-11